Author Published Year
Was the research described as randomized?
Was the approach of randomization
appropriate?
Was the research described
blinding? as
Was the approach of
blinding appropriate?
Was there a presentation
of withdrawals
and dropouts?
Was there a presentation
of the inclusion /exclusion
criteria?
Was the approach used to assess
adverse effects described?
Was the approach
of statistical
analysis described?
Total
Ichikawa 2017 1 1 1 1 1 1 1 1 8
Loebel 2016 1 1 1 1 1 1 1 1 8
Handen 2015 1 1 1 1 1 1 1 1 8
Scahill 2015 1 1 1 1 1 1 1 1 8
Pearson 2013 1 0 1 0 1 1 1 1 6
Owen 2009 1 1 1 0 1 1 1 1 7
Marcus 2009 1 0 1 0 1 1 0 1 5
Handen 2008 1 0 1 0 1 1 1 1 6
Arnold 2006 1 0 1 0 1 1 1 1 6
Aman 2005 1 1 1 1 1 1 1 1 8
Shea 2004 1 1 1 0 1 1 1 1 7
Handen 2000 1 1 1 0 1 1 0 1 6
Quintana 1995 1 0 1 0 0 1 1 1 5
sTable 1 The Modified Jadad scores of the included studies
sTable 2. List of studies removed after full-text reviewing
Study Title Reason of Exclusion
Kent 2013 Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind,
Placebo-Controlled Study Did not report the result of hyperactivity measure
Nagaraj 2006 Risperidone in Children with Autism: Randomized, Placebo-Controlled, Double-Blind
Study Did not report the result of hyperactivity measure
Luby 2006 Risperidone in Preschool Children with Autistic Spectrum Disorders: An Investigation of
Safety and Efficacy Did not report the result of hyperactivity measure
Findling 2013
A Randomized Controlled Trial Investigating the Safety and Efficacy of Aripiprazole in the Long-Term Maintenance Treatment of Pediatric Patients with Irritability Associated with Autistic Disorder
Did not report the result of hyperactivity measure
Harfterkamp2012 A Randomized Double-Blind Study of Atomoxetine Versus Placebo for Attention-
Deficit/Hyperactivity Disorder Symptoms in Children with Autism Spectrum Disorder Did not report the result of hyperactivity measure Eslamzadeh 2018 Assessment the Efficacy of Atomoxetine in Autism Spectrum Disorders: A Randomized,
Double-Blind, Placebo-Controlled Trial Did not report the result of hyperactivity measure McCracken 2002 Risperidone in children with autism and serious behavioral problems Outcome data not appropriate
Pandina 2007 Risperidone Improves Behavioral Symptoms in Children with Autism in a Randomized,
Double-Blind, Placebo-Controlled Trial Secondary analysis of previous data
Scahill 2017 Using a Patient-Centered Outcome Measure to Test Methylphenidate Versus Placebo in
Children with Autism Spectrum Disorder Secondary analysis of previous data
Hellings 2006 A crossover study of risperidone in children, adolescents and adults
with mental retardation Include adult population